Treatment of Acute Promyelocytic Leukemia with Single Agent Arsenic Trioxide: Experience from a Tertiary Care Center in India

Karthik Udupa, Joseph Thomas, Chethana Babu Udupa, V. S. Binu, Prahlad Sharan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

APML is a highly curable hematological malignancy which is treated with differentiation agents and chemotherapy. The morbidity caused by chemotherapy in the treatment of APML is a great cause of concern. We treated 12 patients with newly diagnosed APML with single agent arsenic trioxide between 2010 and 2014 irrespective of risk stratification. Out of 12 patient 2 patients died during induction. All the ten patients who completed induction, completed their consolidation and maintenance without any delays. One out of these ten patients relapsed 10 months after treatment. The remaining nine patients (80 %) are in molecular remission and are under regular follow up. The toxicity with arsenic was negligible and was very well tolerated. Hence arsenic trioxide as single agent can be offered as a standard alternative regimen to ATRA based chemotherapy in patients with economic constraints.

Original languageEnglish
Pages (from-to)45-48
Number of pages4
JournalIndian Journal of Hematology and Blood Transfusion
Volume33
Issue number1
DOIs
Publication statusPublished - 01-03-2017

Fingerprint

Acute Promyelocytic Leukemia
Tertiary Care Centers
India
Drug Therapy
Therapeutics
Arsenic
Hematologic Neoplasms
arsenic trioxide
Maintenance
Economics
Morbidity

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{6837d8ae5a8d4eae80d91106b090f7c0,
title = "Treatment of Acute Promyelocytic Leukemia with Single Agent Arsenic Trioxide: Experience from a Tertiary Care Center in India",
abstract = "APML is a highly curable hematological malignancy which is treated with differentiation agents and chemotherapy. The morbidity caused by chemotherapy in the treatment of APML is a great cause of concern. We treated 12 patients with newly diagnosed APML with single agent arsenic trioxide between 2010 and 2014 irrespective of risk stratification. Out of 12 patient 2 patients died during induction. All the ten patients who completed induction, completed their consolidation and maintenance without any delays. One out of these ten patients relapsed 10 months after treatment. The remaining nine patients (80 {\%}) are in molecular remission and are under regular follow up. The toxicity with arsenic was negligible and was very well tolerated. Hence arsenic trioxide as single agent can be offered as a standard alternative regimen to ATRA based chemotherapy in patients with economic constraints.",
author = "Karthik Udupa and Joseph Thomas and Udupa, {Chethana Babu} and Binu, {V. S.} and Prahlad Sharan",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s12288-016-0668-9",
language = "English",
volume = "33",
pages = "45--48",
journal = "Indian Journal of Hematology and Blood Transfusion",
issn = "0971-4502",
publisher = "Springer India",
number = "1",

}

Treatment of Acute Promyelocytic Leukemia with Single Agent Arsenic Trioxide : Experience from a Tertiary Care Center in India. / Udupa, Karthik; Thomas, Joseph; Udupa, Chethana Babu; Binu, V. S.; Sharan, Prahlad.

In: Indian Journal of Hematology and Blood Transfusion, Vol. 33, No. 1, 01.03.2017, p. 45-48.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of Acute Promyelocytic Leukemia with Single Agent Arsenic Trioxide

T2 - Experience from a Tertiary Care Center in India

AU - Udupa, Karthik

AU - Thomas, Joseph

AU - Udupa, Chethana Babu

AU - Binu, V. S.

AU - Sharan, Prahlad

PY - 2017/3/1

Y1 - 2017/3/1

N2 - APML is a highly curable hematological malignancy which is treated with differentiation agents and chemotherapy. The morbidity caused by chemotherapy in the treatment of APML is a great cause of concern. We treated 12 patients with newly diagnosed APML with single agent arsenic trioxide between 2010 and 2014 irrespective of risk stratification. Out of 12 patient 2 patients died during induction. All the ten patients who completed induction, completed their consolidation and maintenance without any delays. One out of these ten patients relapsed 10 months after treatment. The remaining nine patients (80 %) are in molecular remission and are under regular follow up. The toxicity with arsenic was negligible and was very well tolerated. Hence arsenic trioxide as single agent can be offered as a standard alternative regimen to ATRA based chemotherapy in patients with economic constraints.

AB - APML is a highly curable hematological malignancy which is treated with differentiation agents and chemotherapy. The morbidity caused by chemotherapy in the treatment of APML is a great cause of concern. We treated 12 patients with newly diagnosed APML with single agent arsenic trioxide between 2010 and 2014 irrespective of risk stratification. Out of 12 patient 2 patients died during induction. All the ten patients who completed induction, completed their consolidation and maintenance without any delays. One out of these ten patients relapsed 10 months after treatment. The remaining nine patients (80 %) are in molecular remission and are under regular follow up. The toxicity with arsenic was negligible and was very well tolerated. Hence arsenic trioxide as single agent can be offered as a standard alternative regimen to ATRA based chemotherapy in patients with economic constraints.

UR - http://www.scopus.com/inward/record.url?scp=84961590896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961590896&partnerID=8YFLogxK

U2 - 10.1007/s12288-016-0668-9

DO - 10.1007/s12288-016-0668-9

M3 - Article

AN - SCOPUS:84961590896

VL - 33

SP - 45

EP - 48

JO - Indian Journal of Hematology and Blood Transfusion

JF - Indian Journal of Hematology and Blood Transfusion

SN - 0971-4502

IS - 1

ER -